ClinicalTrials.gg
Active, not recruitingNCT06821542Updated Aug 25, 2026

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

A Phase 3 interventional study of INCA034176 and Best Available Therapy (BAT) in Chronic Graft-versus-host-disease, sponsored by Incyte Corporation. Active, not recruiting at 130 sites in 16 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome — 5 open to participants now, 9 under way, 3 of them phase 3. axatilimab · Bronchiolitis Obliterans Syndrome.

Enrollment
10th of 10
9 · median 50
Started
2025
with 4 others
Phase 3
3 of 10
1 open now
Registered
7th of 10
by date
Lead sponsor
5 of 10
Incyte Corporation

Among the 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome, this one is the 10th largest by enrollment, is one of 5 that started in 2025, is one of 3 in phase 3, and was the 7th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

5 of the 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About axatilimab

axatilimab: first FDA approval 2024 (NIKTIMVO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome, or all of them as a file.
02

Study summary

This study will be conducted to compare Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.

03

Conditions studied

  • Chronic Graft-versus-host-disease

Keywords

  • cGVHD
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 12 years at the time of signing the ICF.
  • Active, moderate to severe cGVHD, requiring systemic immune suppression.
  • Participants with or recurrent cGVHD who have received at least 2 , including and ruxolitinib.
  • Concomitant use of systemic corticosteroids is allowed. Participants on systemic corticosteroids must be on a stable dose of corticosteroids for at least 2 weeks prior to C1D1. Topical and inhaled corticosteroid agents are allowed.
  • Participants must accept to be treated with one of the following BAT options on C1D1: CNI (cyclosporine or tacrolimus), ECP, MMF, an mTOR inhibitor (everolimus or sirolimus), rituximab, pentostatin, proteasome inhibitors, imatinib, or ibrutinib.
  • History of allo-HCT from any donor HLA type (related or unrelated donor with any degree of HLA matching) using any graft source (bone marrow, peripheral blood stem cells, or cord blood). Recipients of myeloablative, nonmyeloablative, or reduced-intensity conditioning are eligible.

Exclusion criteria

Exclusion Criteria:

  • Receipt of more than 1 prior allo-HCT. Prior HCT is allowed.
  • Evidence of relapse of hematologic disease or treatment for relapse after the allo-SCT was performed, including DLI for the treatment of molecular relapse. Note: Participants who have received a scheduled DLI as part of their transplant procedure and not for management of relapse are eligible.
  • Systemic treatment with CNIs or mTOR inhibitors started within 2 weeks prior to C1D1.
  • Severe renal impairment, that is, estimated \< 30 mL/min measured or calculated by Cockcroft-Gault equation in adults and Schwartz formula in pediatric participants, or end-stage renal disease on dialysis.
  • Impaired liver function, defined as total > 1.5 × and/or and AST > 3 × ULN in participants with no evidence of liver cGVHD.
  • History of acute or chronic pancreatitis.
  • Active, symptomatic myositis.
  • Pregnant or breastfeeding.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Axatilimab

    Axatilimab at the protocol-defined dose.

    Drug: INCA034176

  • Experimental
    Best available Treatment (BAT)

    Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.

    Drug: Best Available Therapy (BAT)

Interventions

  • IV infusion

    Also known as: Axatilimab

  • DrugBest Available Therapy (BAT)

    Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.

    Also known as: BAT could include:, • Calcineurin inhibitor (cyclosporine or tacrolimus), • Extracorporeal photopheresis (ECP), • Mycophenolate mofetil (MMF), • A mammalian target of rapamycin (mTOR) inhibitor (everolimus or sirolimus), • Rituximab, • Pentostatin, • Proteasome inhibitors, • Imatinib, • Ibrutinib

06

What researchers measure

Primary outcomes

  1. Objective Response (OR) at 6 months

    Defined for each treatment group as complete response (CR) or partial response (PR) at 6 months (Cycle 7 Day 1, 28-day cycles) in the absence of new systemic therapy for cGVHD. Responses defined by the 2014 NIH consensus criteria.

    Time frame: 6 months

Secondary outcomes

  1. Failure-free survival (FFS)

    Defined as the time from the date of randomization to the date of addition or initiation of another systemic therapy for cGVHD, relapse of underlying disease, or death due to any cause.

    Time frame: Up to 5 years

  2. Proportion of participants with a ≥ 7-point improvement in modified Lee Symptom Scale (mLSS) total score

    Time frame: Up to 5 years

  3. Overall Response at 12 months

    Defined as CR or PR at 12 months in the absence of new systemic therapy for cGVHD.

    Time frame: 12 months

  4. Best Overall Response (BOR)

    Defined as the best response of CR or PR in the first 6 months (up to and including Cycle 7 Day 1), and at any timepoint up to the initiation of new therapy for cGVHD.

    Time frame: Up to 5 years

  5. DOR (in responders only)

    Defined as the time from the date of first response (PR or CR) to the date of progression of cGVHD from baseline scoring, start of new systemic treatment for cGVHD, or death from any cause, whichever comes first. An additional measure of response durability will consider DOR as the time from the date of first response to the date of new systemic therapy for cGVHD or death from any cause, whichever occurs first.

    Time frame: Up to 5 years

  6. Organ-specific response

    Organ-specific response as defined in the protocol.

    Time frame: Up to 5 years

  7. Overall Survival (OS)

    Defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: Up to 5 years

  8. Nonrelapse mortality (NRM)

    Defined as the time from the date of randomization to the date of death not preceded by relapse of primary hematologic disease.

    Time frame: Up to 5 years

  9. Time to primary hematologic disease relapse

    Defined as the time from the date of randomization to the date of relapse.

    Time frame: Up to 5 years

  10. Percent reduction in daily corticosteroid dose at 6 months

    Time frame: 6 months

  11. Proportion of participants who tapered off all corticosteroids at 6 months

    Time frame: 6 months

  12. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    Defined as adverse events reported for the first time or worsening of a pre-existing event after the first dose of study treatment.

    Time frame: Up to 5 years and 30 days

07

Study locations

130 sites

Showing the first 100 of 130 sites across 16 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2028, 35 months after the start.

Of 30 phase 3 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 35 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 12, 2025
StartActual
Jun 4, 2025
Primary completionEst.
May 31, 2028
CompletionEst.
Nov 30, 2032
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06821542
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Feb 12, 2025
Start date
Jun 4, 2025
Primary completion
May 31, 2028 (estimated)
Completion
Nov 30, 2032 (estimated)
Last update
Aug 25, 2026

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axatilimab

Start the discussion